Compare
Cigna vs Quest Diagnostics (CI vs DGX)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Cigna (CI) returned +13.1% and Quest Diagnostics (DGX) +43.4%; so far this year the figures are +6.7% and +47.3%.
Cigna is the larger company by market value, about 2.8 times the size of Quest Diagnostics.
On trailing earnings, CI trades at 12.9 times and DGX at 25.5 times.
Revenue grew +6.8% at CI and +9.1% at DGX over the last year.
CI yields 2.11%. DGX yields 1.32%.
Data as of the latest close. Not investment advice.
Relative performance
| CI | DGX | |
|---|---|---|
| Price | $293.59 | $255.63 |
| 1-day | -2.62% | +0.35% |
| YTD | +6.67% | +47.31% |
| 1 year | +13.10% | +43.40% |
| 3 years | -5.11% | +92.88% |
| Market cap | $77.4B | $28.1B |
| P/E | 12.9 | 25.5 |
| P/S | 0.27 | 2.38 |
| P/B | 1.78 | 3.69 |
| Revenue growth | +6.80% | +9.10% |
| EPS growth | +0.30% | +17.80% |
| Gross margin % | 20.7 | 33.1 |
| Net margin % | 2.1 | 9.5 |
| ROE % | 13.8 | 14.8 |
| Debt / equity | 0.72 | 0.73 |
| FCF yield % | 12.2 | 4.9 |
| Dividend yield % | 2.11 | 1.32 |
| Beta | 0.08 | -0.05 |
| RSI (14) | 49.6 | 66.9 |
| Technical rating |